Recently in the US, certain VCs have become registered advisors as well—and it’s transforming how biotech innovation is funded. At BEP, we’ve taken this one step further by embedding a full-service investment bank alongside our biotech venture capital arm, and all this a few years ago. Here’s why this integrated model works:
Seamless Deal Flow
From academic spinouts to crossover rounds, we source and syndicate capital at every stage—first round to IPO—under one roof, streamlining the biotech venture capital process.
360° Diligence
Our MD/PhD–led team dives deep into science and regulatory pathways while our bankers build robust financial models and market comparable—raising the bar in biotech venture capital assessment.
End-to-End Capital Raising
Series A round cheques today, PIPEs and public offerings tomorrow—portfolio companies never leave the house for their next round, thanks to our unified biotech venture capital and banking model.
Optimized Exits
Controlling roadshows and book‐building in-house lets us move faster and protect valuation in hot sectors like cell & gene therapy—key areas within biotech venture capital.
Stronger Brand & Talent
Thought leadership, joint research, and a one-stop finance shop attract top CEOs, scientists, and analysts to our biotech venture capital ecosystem.
Operational Scale
Shared legal, compliance, and data analytics infrastructures reduce costs and expedite decision-making—boosting our biotech venture capital portfolio efficiency.
Bringing VC and investment banking together isn’t just synergy—it’s a game-changer for biotech venture capital and the future of biotech.
George Syrmalis’s Author Bio
Bioscience Equity Partners (BEP) was founded by a former nuclear medicine specialist, George Syrmalis, who transitioned into biotech venture capital to address the funding and commercialization challenges faced by biotech innovations. With a unique blend of clinical, scientific, and financial expertise, BEP focuses exclusively on biotech, med-tech, and digital health. The firm stands out through its long-term, hands-on investment model, global presence, and strategic partnerships. BEP empowers early-stage companies by providing not just equity funding, but comprehensive life sciences funding solutions and support from lab to IPO—driving the future of personalized, data-driven healthcare.
Also Read :-
